Immune cell therapy for children with leukemia or neuroblastoma after a stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immune cell treatment called ThINKK for children who had a stem cell transplant for leukemia or neuroblastoma. The goal is to see if this therapy can help prevent or fight cancer without causing severe side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 2 and 12 years old.
- Child must have been diagnosed with acute leukemia or neuroblastoma.
- Must have had a stem cell transplant (from a donor) 30 to 90 days before joining.
- Blood tests must show a certain level of natural killer cells (a type of immune cell).
- Child must be expected to live at least 3 more months.
- No current severe graft-versus-host disease (a transplant complication) or active cancer relapse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
This trial tests a new treatment using immune cells (called natural killer cells) derived from stem cells to help fight AML that has returned or not responded to standard therapy. The goal is to see if these cells can safely and effectively control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.